Tango Therapeutics, Inc.
NASDAQ:TNGXBiotechnology
Healthcare
$22.71 -10.03%
-$3.24 today
- Market cap
- $3.85B
- Beta
- 1.19
- P/E (TTM)
- -38.9
- EPS (TTM)
- -$0.75
52W Low $4.60High $34.39
Volume 1.81M
Average 3.67M
Balance Sheet
Inspect the capital base behind the business.
Assets
$398.69M
FY 2025 · Annual
+26.0% YoYLiabilities
$52.51M
FY 2025 · Annual
-55.1% YoYEquity
$346.18M
FY 2025 · Annual
+73.5% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 142.75M | 59.97M | 66.39M | 69.53M | 112.28M |
| Short-term Investments | 342.51M | 306.17M | 270.5M | 188.39M | 230.86M |
| Net Receivables | 2M | 2M | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 567K | 7.14M | 9.65M | 8.43M | 10.62M |
| Total Current Assets | 492.34M | 375.27M | 346.54M | 266.34M | 353.76M |
| Property, Plant & Equipment (Net) | 6.09M | 57.77M | 53.42M | 47.58M | 42.49M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.73M | 3.43M | 2.61M | 2.57M | 2.44M |
| Total Non-current Assets | 7.82M | 61.2M | 56.03M | 50.15M | 44.93M |
| Total Assets | 500.16M | 436.47M | 402.57M | 316.49M | 398.69M |
| Account Payables | 3.23M | 4.45M | 2.79M | 1.6M | 1.18M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 52K | 35K | 0 | 0 | 0 |
| Deferred Revenue | 26.02M | 31.79M | 25.67M | 17.62M | 0 |
| Other Current Liabilities | 666K | 1.27M | 7.49M | 1.74M | 1.29M |
| Total Current Liabilities | 40.69M | 55.55M | 45.94M | 38.17M | 21.68M |
| Long-term Debt | 0 | 0 | 0 | 0 | 30.83M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 114.72M | 92.09M | 66.68M | 44.77M | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 114.72M | 131.45M | 103.52M | 78.81M | 30.83M |
| Total Liabilities | 155.41M | 186.99M | 149.46M | 116.98M | 52.51M |
| Common Stock | 88K | 88K | 102K | 108K | 136K |
| Retained Earnings | (161.34M) | (269.51M) | (371.26M) | (501.56M) | (603.15M) |
| Accumulated OCI | (765K) | (3.71M) | 186K | 336K | 224K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 344.75M | 249.48M | 253.11M | 199.52M | 346.18M |
| Total Debt | 1.5M | 41.13M | 38.92M | 36.49M | 33.57M |
| Net Debt | (141.24M) | (18.84M) | (27.47M) | (33.04M) | (78.71M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $86.8M |
| Short-term Investments | $890.7M |
| Other Current | $15.2M |
| Total Current Assets | $992.7M |
| PP&E (Net) | $38.4M |
| Other Non-current | $2.4M |
| Total Non-current Assets | $40.8M |
| Total Assets | $1.0B |
Analysis
Selected assets total $1.0B for Latest. The largest visible component is Short-term Investments at $890.7M, about 86.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 |
How much cash does TNGX have?
Tango Therapeutics, Inc. (TNGX) reported $112.28M in cash and equivalents in fiscal 2025.
How much debt does TNGX carry?
Tango Therapeutics, Inc. (TNGX) reported $33.57M of total debt, with net debt of -$78.71M.
Continue the stock analysis
Jump to another research area for this company.